ARS Pharmaceuticals (SPRY) Total Liabilities (2020 - 2026)
ARS Pharmaceuticals (SPRY) posted Total Liabilities of $226.3 million for Q1 2026, up 6.03% sequentially from $213.4 million in Q4 2025, and up 130.07% YoY from $98.3 million in Q1 2025.
ARS Pharmaceuticals (SPRY) Total Liabilities (2020 - 2026) Analysis & Trends
ARS Pharmaceuticals has reported Total Liabilities for 7 years, with the latest figure at $226.3 million in Q1 2026.
- Quarterly Total Liabilities rose 130.07% year-over-year to $226.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $226.3 million (up 130.07% YoY) and the FY2025 annual result came in at $213.4 million, up 126.16% from the prior year.
- Total Liabilities improved to $226.3 million in Q1 2026 per SPRY's latest filing, from $213.4 million in the prior quarter.
- Over five years, Total Liabilities peaked at $226.3 million in Q1 2026 and troughed at $2.4 million in Q4 2023.
- A 5-year average of $63.9 million and a median of $15.2 million in 2022 frame the typical range for Total Liabilities.
- The sharpest annual moves came in 2022 and 2024: Total Liabilities plunged 80.47% in 2022, then soared 3786.12% in 2024.
- Over 5 years, Total Liabilities stood at $8.5 million in 2022, then tumbled by 71.6% to $2.4 million in 2023, then jumped by 3786.12% to $94.4 million in 2024, then soared by 126.16% to $213.4 million in 2025, then rose by 6.03% to $226.3 million in 2026.
- According to Business Quant data, Total Liabilities over the past three periods registered $226.3 million, $213.4 million, and $225.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 7.18 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 10.02 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.62 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 1.72 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 4.00 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 7.02 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 10.03 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.20 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.35 Bn |
| 10 | ARS Pharmaceuticals | 561.88 Mn | 418.03 Mn | - | 236.98 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 236.98 Mn |
| Mar 31, 2026 | 226.26 Mn |
| Dec 31, 2025 | 213.39 Mn |
| Sep 30, 2025 | 225.15 Mn |
| Jun 30, 2025 | 121.15 Mn |
| Mar 31, 2025 | 98.34 Mn |
| Dec 31, 2024 | 94.36 Mn |
| Sep 30, 2024 | 16.62 Mn |
| Jun 30, 2024 | 6.73 Mn |
| Mar 31, 2024 | 3.72 Mn |
| Dec 31, 2023 | 2.43 Mn |
| Sep 30, 2023 | 11.27 Mn |
| Jun 30, 2023 | 10.20 Mn |
| Mar 31, 2023 | 10.04 Mn |
| Dec 31, 2022 | 8.55 Mn |
| Sep 30, 2022 | 3.99 Mn |
| Jun 30, 2022 | 15.21 Mn |
| Mar 31, 2022 | 19.24 Mn |
| Dec 31, 2021 | 16.68 Mn |
| Sep 30, 2021 | 20.43 Mn |